Eli Lilly and Company - Sale Or Purchase of Stock

Eli Lilly and Company's Fiscal Year is From January To December - All Figures are in USD, Billions.

The item "Sale-Or-Purchase-of-Stock" stands at -4.65 Billion United States Dollars for the trailing twelve months (TTM) period ending 09/30/2025, the lowest value since 12/31/2022.

Eli Lilly and Company's third quarter result of -0.7081 Billion USD for the item "Sale Or Purchase of Stock" represents a decrease of -2.30 percent compared to it's second quarter result.

Also, Eli Lilly and Company's third quarter result of -0.7081 Billion USD for the item "Sale Or Purchase of Stock" represents a decrease of -58.73 percent compared to it's third quarter result of last year.

Looking again at the trailing twelve months series (TTM), Eli Lilly and Company's third quarter result of -4.65 Billion USD for the item "Sale Or Purchase of Stock" represents a decrease of -5.97 percent compared to it's second quarter result.


Regarding the One-Year-Change of the series, the current value constitutes an decrease of -4.96 Billion United States Dollars compared to the value the year prior.
The 1 year change is -4.96 Billion United States Dollars.
The 3 year change is 0.5958 Billion United States Dollars.
The 5 year change is -2.85 Billion United States Dollars.
The 10 year change is -3.86 Billion United States Dollars.

The Serie's long term average value is -2.20 Billion United States Dollars. It's latest available value, on 09/30/2025, is -2.45 Billion United States Dollars lower, compared to it's long term average value.
The Serie's change in United States Dollars from it's minimum value, on 06/30/2019, to it's latest available value, on 09/30/2025, is +4.45 Billion.
The Serie's change in United States Dollars from it's maximum value, on 09/30/2024, to it's latest available value, on 09/30/2025, is -4.96 Billion.